Ex­clu­sive: Sanofi, Astel­las ven­ture arms add cash to Avi­lar's 'AT­AC' mis­sion

The ven­ture arms of Sanofi and Astel­las have grown their in­vest­ment in Avi­lar Ther­a­peu­tics to help steer the biotech through a niche of the grow­ing pro­tein degra­da­tion field.

Med­ical Ex­cel­lence Cap­i­tal al­so joined the Big Phar­ma’s in­vest­ment teams, along with orig­i­nal in­vestor RA Cap­i­tal. The com­pa­ny orig­i­nal­ly an­nounced a $60 mil­lion com­mit­ment from RA Cap­i­tal in 2021, with the round now at $75 mil­lion, CEO Daniel Grau told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER